Highlights: GLP-1 users had a 37% higher hair loss risk than SGLT-2 inhibitor users, although the overall risk remained low Most cases involved temporary, non-scarring hair loss linked to rapid weight loss and nutritional changes Experts recommend maintaining good nutrition and consulting a doctor rather than stopping GLP-1 treatment Weight loss drugs called GLP-1 receptor agonists, including Ozempic, Wegovy, Mounjaro, and Zepbound, are transforming the treatment of obesity and type 2 diabetes by improving blood sugar control and promoting substantial weight loss
Sections were subsequently developed using the avidin-biotin peroxidase complex system (ABC kit, BOSTER Ltd
Las tasas de discontinuacin del tratamiento debido a eventos adversos fueron del 8,7% y el 9,7% con orforglipron 12 mg y 36 mg , frente al 4,5% y el 4,9% con semaglutida oral en ACHIEVE-3
What a Licensed Clinician Typically Screens For Before approving GLP-1 treatment, providers review several critical safety factors to determine whether treatment is appropriate: Personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (absolute contraindications)
Sometimes this normal effect can develop into gastroparesis